Confusion Regarding Duration of Insulin Action
暂无分享,去创建一个
[1] Lutz Heinemann,et al. Measurement of insulin absorption and insulin action. , 2004, Diabetes technology & therapeutics.
[2] L. Heinemann,et al. Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy , 2009, Diabetes Care.
[3] I. Hirsch,et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. , 2005, Diabetes care.
[4] S. Mudaliar,et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. , 1999, Diabetes care.
[5] L. Heinemann,et al. Dose–response relationship of insulin glulisine in subjects with type 1 diabetes , 2009, Diabetes care.
[6] L. Heinemann,et al. Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin , 1998, Diabetes Care.
[7] T. Bailey,et al. Guidelines for Optimal Bolus Calculator Settings in Adults , 2011, Journal of diabetes science and technology.
[8] W. Roberts,et al. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. , 2004, Clinical chemistry.
[9] Eyal Dassau,et al. Bolus calculator: a review of four "smart" insulin pumps. , 2008, Diabetes technology & therapeutics.
[10] R. DeFronzo,et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.
[11] L. Heinemann,et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. , 1998, Diabetes care.
[12] S. Steiner,et al. A novel insulin formulation with a more rapid onset of action , 2008, Diabetologia.
[13] S. Donath,et al. Poor adherence to integral daily tasks limits the efficacy of CSII in youth , 2011, Pediatric diabetes.
[14] J. Tauber,et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. , 2000, Diabetes care.
[15] L. Heinemann,et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. , 2005, Diabetes care.
[16] Subcutaneous Injection versus Subcutaneous Infusion of Insulin: Are the Rates of Absorption Truly the Same? , 2011, Journal of diabetes science and technology.
[17] B. Olsen,et al. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes , 2000, European Journal of Pediatrics.
[18] Lutz Heinemann,et al. Variability of insulin absorption and insulin action. , 2002, Diabetes technology & therapeutics.
[19] B. Sugarman,et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. , 2009, Diabetes technology & therapeutics.
[20] K. Minaker,et al. Escape of hepatic glucose production during hyperglycemic clamp. , 1989, The American journal of physiology.
[21] John Walsh,et al. Guidelines for Insulin Dosing in Continuous Subcutaneous Insulin Infusion Using New Formulas from a Retrospective Study of Individuals with Optimal Glucose Levels , 2010, Journal of diabetes science and technology.
[22] L. Heinemann,et al. Ultrafast-Acting Insulins: State of the Art , 2012, Journal of diabetes science and technology.
[23] L. Heinemann,et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. , 2005, Diabetes care.